Mebendazole, an antiparasitic drug, inhibits drug transporters expression in preclinical model of gastric peritoneal carcinomatosis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Toxicology in Vitro

• Publication date

  2017-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.tiv.2017.06.007PMID 28606429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model.

  2015cited by this paper
• Abstract 4012: Large-scale characterization of DNA methylation changes in human gastric carcinomas with and without metastasis

  2014cited by this paper
• Differentially expressed genes responsible for insensitivity of CD34+ cells to kinase inhibitors in patients with chronic myeloid leukemia

  2013cited by this paper
• Clinical implication of 14-3-3 epsilon expression in gastric cancer.

  2012cited by this paper
• Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures.

  2012cited by this paper
• Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites

  2011cited by this paper
• Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

  2011cited by this paper
• Targeted Therapies for Gastric Cancer

  2011cited by this paper
• Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Association between IL-17A, -17F and MIF polymorphisms predispose to CpG island hyper-methylation in gastric cancer.

  2010cited by this paper
• New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.

  2010cited by this paper
• Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells.

  2010cited by this paper
• The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments.

  2009cited by this paper
• Functional Characterization of Multidrug and Toxin Extrusion Protein 1 as a Facilitative Transporter for Fluoroquinolones

  2009cited by this paper
• Reversal of P‐glycoprotein‐mediated multi‐drug resistance by the E3 ubiquitin ligase Cbl‐b in human gastric adenocarcinoma cells

  2009cited by this paper
• The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer

  2009cited by this paper
• The Inhibition of Human Multidrug and Toxin Extrusion 1 Is Involved in the Drug-Drug Interaction Caused by Cimetidine

  2009cited by this paper
• Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function

  2009cited by this paper
• Establishment and conventional cytogenetic characterization of three gastric cancer cell lines.

  2009cited by this paper
• Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

  2008cited by this paper
• Mebendazole Induces Apoptosis via Bcl-2 Inactivation in Chemoresistant Melanoma Cells

  2008cited by this paper
• Analyzing real-time PCR data by the comparative CT method

  2008cited by this paper
• Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice

  2008cited by this paper
• Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax.

  2007cited by this paper
• Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.

  2007cited by this paper
• Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges

  2007cited by this paper
• Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.

  2007cited by this paper
• Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.

  2007cited by this paper
• Targeting multidrug resistance in cancer

  2006cited by this paper
• Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

  2006cited by this paper
• Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data.

  2006cited by this paper
• Gastric cancer--new therapeutic options.

  2006cited by this paper
• Immunomodulatory effect of various anti-parasitics: a review

  2005cited by this paper
• Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

  2005cited by this paper
• Regulation of multidrug resistance by ribosomal protein L6 in gastric cancer cells

  2005cited by this paper
• ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal

  2005cited by this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.

  2003cited by this paper
• Functional consequence of MDR1 expression on imatinib intracellular concentrations.

  2003cited by this paper
• ABCG2 (BCRP) expression in normal and malignant hematopoietic cells

  2003cited by this paper
• Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?

  2003cited by this paper
• Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.

  2002cited by this paper
• Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation

  2002cited by this paper
• The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

  2001cited by this paper
• Benzimidazoles in the treatment of alveolar echinococcosis: a comparative study and review of the literature.

  2000cited by this paper
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  2000cited by this paper
• Association of 5' CpG demethylation and altered chromatin structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells.

  1999cited by this paper
• Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias.

  1998cited by this paper
• Benzimidazoles, potent anti-mitotic drugs: substrates for the P-glycoprotein transporter in multidrug-resistant cells.

  1994cited by this paper
• The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles.

  1988cited by this paper
• Anthelmintic efficacy of mebendazole suspension against induced helminth infections in South African sheep and cattle.

  1984cited by this paper
• Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients.

  1982cited by this paper

• Mebendazole impairs the expression and function of enzymes in nucleotide metabolism pathways, leading to Selective Cytotoxicity, Cell Cycle Arrest, and Damage to Cell Morphology in Gastric Cancer.

  2026cites this paper
• An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer

  2025cites this paper
• Repurposing of Mebendazole as an Anticancer Agent: A Review

  2025cites this paper
• Transcriptome analysis displays new molecular insights into the mechanisms of action of Mebendazole in gastric cancer cells

  2024cites this paper
• Mebendazole targets essential proteins in glucose metabolism leading gastric cancer cells to death.

  2023cites this paper
• HPMA Copolymer Mebendazole Conjugate Allows Systemic Administration and Possesses Antitumour Activity In Vivo

  2022cites this paper
• Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics

  2022cites this paper
• HPMA-Based Polymer Conjugates for Repurposed Drug Mebendazole and Other Imidazole-Based Therapeutics

  2021cites this paper
• Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment

  2021cites this paper
• The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs

  2020cites this paper
• Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics.

  2020cites this paper
• Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Diseases or New Options for Other Diseases?

  2019cites this paper
• Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature

  2019influential citation
• Drug repurposing: mebendazole as effective antitumor agent. Are we seeing the whole story?

  2018cites this paper